$同源康医药-B(0_老虎社区_美港股上老虎

$同源康医药-B(02410)$ TY-9591作为新一代EGFR抑制剂，在耐药突变和脑转移等难治场景具备差异化优势，不是简单的靶点跟随，护城河正在逐步筑起。

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":606233630639224,"tweetId":"606233630639224","gmtCreate":1789029843498,"gmtModify":1789029846031,"author":{"id":4218427800237090,"idStr":"4218427800237090","authorId":4218427800237090,"authorIdStr":"4218427800237090","name":"莎士比亚的微笑","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[],"fanSize":11,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"title":"","html":"<html><head></head><body><p><a href=\"https://laohu8.com/S/02410\">$同源康医药-B(02410)$ </a> TY-9591作为新一代EGFR抑制剂，在耐药突变和脑转移等难治场景具备差异化优势，不是简单的靶点跟随，护城河正在逐步筑起。</p></body></html>","htmlText":"<html><head></head><body><p><a href=\"https://laohu8.com/S/02410\">$同源康医药-B(02410)$ </a> TY-9591作为新一代EGFR抑制剂，在耐药突变和脑转移等难治场景具备差异化优势，不是简单的靶点跟随，护城河正在逐步筑起。</p></body></html>","text":"$同源康医药-B(02410)$ TY-9591作为新一代EGFR抑制剂，在耐药突变和脑转移等难治场景具备差异化优势，不是简单的靶点跟随，护城河正在逐步筑起。","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/606233630639224","repostId":0,"isVote":1,"tweetType":1,"viewCount":76,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":["02410"],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":130,"optionInvolvedFlag":false,"subscribersOnly":false,"subscribersOnlyAccessible":false,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"hasMoreComment":false,"orderType":2}